Costly New Alzheimer’s Drug Could Force Medicare to Restrict Access

Aside from the medicine itself, there is the cost of infusing the drug, brain-imaging tests and doctor visits, said Scott A. Small, director of Columbia University’s Alzheimer’s Disease Research Center. The total cost will be approximately $100,000 annually per patient, he said. [read more]

Source: The Wall Street Journal